FDA’s New Oncology Office May Not Include Skin Cancer Products

Skin cancer agents are likely to remain in the Division of Dermatologic & Dental Drug Products, FDA’s Colangelo says. It is “undecided” whether prostate cancer agents will be shifted to the new Office of Oncology Drug Products.